{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=39",
    "query": {
      "intervention": "Placebo",
      "page": 39
    },
    "page_size": 10
  },
  "pagination": {
    "page": 39,
    "page_size": 10,
    "total_count": 33151,
    "total_pages": 3316,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=40&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo&page=38&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-05T13:18:27.037Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT06343779",
      "title": "Study of Oral Deucrictibant Soft Capsule for On-Demand Treatment of Angioedema Attacks in Adolescents and Adults With Hereditary Angioedema",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Hereditary Angioedema",
        "Hereditary Angioedema Type I",
        "Hereditary Angioedema Type II",
        "Hereditary Angioedema Types I and II",
        "Hereditary Angioedema Attack",
        "Hereditary Angioedema With C1 Esterase Inhibitor Deficiency",
        "Hereditary Angioedema - Type 1",
        "Hereditary Angioedema - Type 2",
        "C1 Esterase Inhibitor [C1-INH] Deficiency",
        "C1 Esterase Inhibitor Deficiency",
        "C1 Esterase Inhibitor, Deficiency of",
        "C1 Inhibitor Deficiency",
        "Hereditary Angioedema - Type 3",
        "Hereditary Angioedema Type III"
      ],
      "interventions": [
        {
          "name": "Deucrictibant, Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharvaris Netherlands B.V.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "12 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "12 Years to 75 Years"
      },
      "enrollment_count": 134,
      "start_date": "2024-02-26",
      "completion_date": "2025-10-17",
      "has_results": false,
      "last_update_posted_date": "2025-11-21",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 13,
      "location_summary": "Birmingham, Alabama • Paradise Valley, Arizona • Little Rock, Arkansas + 10 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Paradise Valley",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "San Diego",
          "state": "California"
        },
        {
          "city": "Santa Monica",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06343779"
    },
    {
      "nct_id": "NCT00903396",
      "title": "Palonosetron Hydrochloride in Preventing Nausea and Vomiting Caused by Radiation Therapy in Patients With Primary Abdominal Cancer",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Anal Cancer",
        "Carcinoma of the Appendix",
        "Colorectal Cancer",
        "Extrahepatic Bile Duct Cancer",
        "Gallbladder Cancer",
        "Gastric Cancer",
        "Gastrointestinal Carcinoid Tumor",
        "Liver Cancer",
        "Nausea and Vomiting",
        "Pancreatic Cancer",
        "Primary Peritoneal Cavity Cancer",
        "Small Intestine Cancer"
      ],
      "interventions": [
        {
          "name": "palonosetron hydrochloride",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Alliance for Clinical Trials in Oncology",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 7,
      "start_date": "2009-09",
      "completion_date": "2013-05",
      "has_results": true,
      "last_update_posted_date": "2017-11-24",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 69,
      "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Moline, Illinois + 37 more",
      "locations": [
        {
          "city": "Scottsdale",
          "state": "Arizona"
        },
        {
          "city": "Jacksonville",
          "state": "Florida"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Moline",
          "state": "Illinois"
        },
        {
          "city": "Elkhart",
          "state": "Indiana"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00903396"
    },
    {
      "nct_id": "NCT03253926",
      "title": "Effect of Lorcaserin on Cannabis Withdrawal and Self-administration",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cannabis Use"
      ],
      "interventions": [
        {
          "name": "Lorcaserin",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Marijuana",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "New York State Psychiatric Institute",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "21 Years to 50 Years"
      },
      "enrollment_count": 15,
      "start_date": "2017-09-05",
      "completion_date": "2021-12-31",
      "has_results": true,
      "last_update_posted_date": "2022-07-26",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03253926"
    },
    {
      "nct_id": "NCT04927585",
      "title": "Evaluating the Safety and Immunogenicity of Polyvalent DNA/gp120 HIV Vaccine in Healthy, HIV-uninfected Adults",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "HIV Infections"
      ],
      "interventions": [
        {
          "name": "env (A,B,C,A/E)/gag (C) DNA Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "gp120 (A,B,C,A/E) Protein Vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "GLA-SE adjuvant",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Placebo",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Worcester HIV Vaccine",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "ALL",
        "summary": "18 Years to 50 Years"
      },
      "enrollment_count": 42,
      "start_date": "2021-07-08",
      "completion_date": "2023-12-07",
      "has_results": false,
      "last_update_posted_date": "2024-04-09",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "Boston, Massachusetts",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04927585"
    },
    {
      "nct_id": "NCT01499017",
      "title": "A Single Dose Study Of PF-06291874 In Healthy Adult Subjects",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PF-06291874 or Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pfizer",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 9,
      "start_date": "2011-11",
      "completion_date": "2012-01",
      "has_results": false,
      "last_update_posted_date": "2012-01-31",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "New Haven, Connecticut",
      "locations": [
        {
          "city": "New Haven",
          "state": "Connecticut"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01499017"
    },
    {
      "nct_id": "NCT01999868",
      "title": "Efficacy of Ustekinumab Followed by Abatacept for the Treatment of Psoriasis Vulgaris",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Psoriasis"
      ],
      "interventions": [
        {
          "name": "Ustekinumab",
          "type": "BIOLOGICAL"
        },
        {
          "name": "Abatacept",
          "type": "BIOLOGICAL"
        },
        {
          "name": "UST Placebo",
          "type": "DRUG"
        },
        {
          "name": "ABA Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL",
        "DRUG"
      ],
      "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "18 Years to 65 Years"
      },
      "enrollment_count": 108,
      "start_date": "2014-03-19",
      "completion_date": "2018-03-01",
      "has_results": true,
      "last_update_posted_date": "2019-01-15",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 8,
      "location_summary": "Los Angeles, California • Chicago, Illinois • New Orleans, Louisiana + 5 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "New Orleans",
          "state": "Louisiana"
        },
        {
          "city": "Ann Arbor",
          "state": "Michigan"
        },
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01999868"
    },
    {
      "nct_id": "NCT02165397",
      "title": "Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Waldenström's Macroglobulinemia"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Pharmacyclics LLC.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 181,
      "start_date": "2014-07-07",
      "completion_date": "2019-11-07",
      "has_results": true,
      "last_update_posted_date": "2021-03-03",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 10,
      "location_summary": "Los Angeles, California • Palo Alto, California • Denver, Colorado + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Palo Alto",
          "state": "California"
        },
        {
          "city": "Denver",
          "state": "Colorado"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02165397"
    },
    {
      "nct_id": "NCT03224182",
      "title": "A Study of Intravesical Qapzola (Apaziquone) as a Surgical Adjuvant in Participants Undergoing Transurethral Resection of Bladder Tumor (TURBT)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Bladder Cancer"
      ],
      "interventions": [
        {
          "name": "Qapzola",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Spectrum Pharmaceuticals, Inc",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "89 Years",
        "sex": "ALL",
        "summary": "18 Years to 89 Years"
      },
      "enrollment_count": 118,
      "start_date": "2017-08-04",
      "completion_date": "2019-09-26",
      "has_results": true,
      "last_update_posted_date": "2021-09-28",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "Madison, Wisconsin",
      "locations": [
        {
          "city": "Madison",
          "state": "Wisconsin"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03224182"
    },
    {
      "nct_id": "NCT04329923",
      "title": "The PATCH Trial (Prevention And Treatment of COVID-19 With Hydroxychloroquine)",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "COVID-19"
      ],
      "interventions": [
        {
          "name": "Hydroxychloroquine Sulfate 400 mg twice a day",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine Sulfate 600 mg twice a day",
          "type": "DRUG"
        },
        {
          "name": "Hydroxychloroquine Sulfate 600 mg once a day",
          "type": "DRUG"
        },
        {
          "name": "Placebo oral tablet",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Ravi Amaravadi, MD",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 173,
      "start_date": "2020-04-09",
      "completion_date": "2020-11-13",
      "has_results": true,
      "last_update_posted_date": "2020-12-10",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04329923"
    },
    {
      "nct_id": "NCT03014323",
      "title": "Racial Differences in Vagal Control of Glucose Homeostasis, Chronic Study",
      "overall_status": "WITHDRAWN",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Insulin Sensitivity",
        "Oxidative Stress"
      ],
      "interventions": [
        {
          "name": "Galantamine",
          "type": "DRUG"
        },
        {
          "name": "Placebo",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Vanderbilt University Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "60 Years",
        "sex": "FEMALE",
        "summary": "18 Years to 60 Years · Female only"
      },
      "enrollment_count": 0,
      "start_date": "2017-01",
      "completion_date": "2018-12",
      "has_results": false,
      "last_update_posted_date": "2018-08-13",
      "last_synced_at": "2026-11-05T13:18:27.037Z",
      "location_count": 1,
      "location_summary": "Nashville, Tennessee",
      "locations": [
        {
          "city": "Nashville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03014323"
    }
  ]
}